Day: February 6, 2025

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM   Location: Virtual A live webcast of the presentation will be available via the Upcoming Events section of the Company’s investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay will be accessible for 90 days following the event. Leerink Partners Global Healthcare ConferenceFormat: One-on-One meetingsDate and Time: Wednesday,...

ORANGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2024 financial results on Thursday, Feb. 27, 2025, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/oawc6g57 A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same web links and will remain available for approximately 12 months. About Alignment HealthAlignment Health is championing a new path in senior care that...

Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing the clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol, Allarity will capitalize and expand on the ongoing phase 2 clinical trial data to optimize the dose of stenoparib and to refine the DRP® patient selection criteria in order to maximize the clinical benefit from stenoparib. An in-depth review of Allarity’s maturing clinical data, in collaboration with leading...

HOLLYWOOD, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), NV5, a provider of technology, certification, and consulting solutions, announced today that it has been awarded $5 million in substation design contracts by Northeast utilities. These projects will strengthen electrical grid reliability and support the resiliency of New York and New Jersey utility infrastructure. The contract awards continue the expansion of NV5’s relationship with Northeast electric utilities and promotes double-digit organic growth with the Northeast utility sector. NV5’s engineers will design substation infrastructure to expand the capacity of existing substations and connect to underground electrical distribution. Following the design phase of the project, NV5 will be well positioned to enhance the contract...

Results from the Phase 1 single ascending dose study support proceeding to develop a Phase 2 trial for the prevention of kidney transplant rejection TNX-1500 blocked the primary and secondary antibody responses to a test antigen at the 10 mg/kg and 30 mg/kg i.v. doses TNX-1500 showed mean half-life of 34-38 days for the 10 mg/kg and 30 mg/kg doses supporting monthly dosing for future efficacy trials TNX-1500 was generally well-tolerated with a favorable safety profile Anti-CD40L has multiple potential indications in addition to solid organ and bone marrow transplantation including autoimmune diseases: potential pipeline in a product CHATHAM, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a...

CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will participate in the following upcoming investor conferences: BIO CEO & Investor ConferenceFormat: “IPO Class of 2024 Panel” and one-on-one meetingsDate: February 10, 2025Location: New York, NY Registered conference attendees may schedule one-on-one meetings with Actuate management via the conference scheduling platform. B. Riley Precision Oncology & Radiopharma ConferenceFormat: Fireside...

HERZLIYA, Israel, Feb. 06, 2025 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ:PLTK) announced today that it will release financial results for the fourth quarter of 2024 before U.S. markets open on Thursday, February 27, 2025. On the same day, Playtika management will hold a conference call to discuss the results at 5:30 AM Pacific Time, 8:30 AM Eastern Time. A live webcast of the conference call and earnings release materials will be available on Playtika’s Investor Relations website at investors.playtika.com. About PlaytikaPlaytika (NASDAQ:PLTK) is a mobile gaming entertainment and technology market leader with a portfolio of multiple game titles. Founded in 2010, Playtika was among the first to offer free-to-play social games on social networks and, shortly after, on mobile platforms. Headquartered in Herzliya, Israel, and...

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all cervical cancer cases worldwide are caused by HPV infection Up to $2 million in grant funding may be provided by NIAID to support DARE-HPV development, bringing total non-dilutive funding for DARE-HPV advancement to up to $12 million SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it received a Notice of Award of a grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The award will support non-clinical activities to support the development of...

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) — via IBN — Torr Metals Inc. (“Torr” or the “Company“) (TSX-V: TMET.V), announces the successful closing of the final tranche (the “Final Tranche”) of its oversubscribed non-brokered private placement (the “Private Placement”) in the Company’s press release on September 17, 2024, bringing total proceeds to $630,560. Pursuant to the closing of the Final Tranche, the Company issued 1,382,500 non-flow-through units of the Company (each, a “NFT Unit”) at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of $138,250. “We sincerely appreciate our shareholders’ strong support in this oversubscribed financing,” stated Malcolm Dorsey, CEO of Torr Metals. “With this funding, we are fully funded to take Filion to the next level, refining...

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFormat:      Corporate PresentationDate and Time:     February 12, 2025, 10:00 a.m. ESTLocation:     VirtualWebcast Link:     Click Here       Leerink Partners Global Healthcare ConferenceFormat:     Fireside ChatDate and Time:     March 10, 2025, 4:20 p.m. ESTLocation:     Miami, FloridaWebcast Link:     Click Here       Barclays...